What it's for (Indications)
- This combination medication, comprising neomycin, polymyxin B, bacitracin, and lignocaine, is primarily indicated for the prevention and treatment of minor bacterial skin infections.
- Such infections commonly occur in small cuts, scrapes, abrasions, and minor burns (first-degree or superficial second-degree).
- The broad-spectrum antibacterial components work synergistically to cover a wide range of common pathogenic bacteria, including both Gram-positive and Gram-negative organisms, thereby reducing the risk of infection and supporting the natural healing process of the affected skin area.
- The inclusion of lignocaine (lidocaine), a local anesthetic, provides effective symptomatic relief from pain and itching that frequently accompanies these superficial skin injuries, enhancing patient comfort.
- This formulation is exclusively designed for external topical application to the skin surface to address localized dermatological conditions.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For external topical use only. Adults and children 2 years of age and older should clean the affected area thoroughly with mild soap and water, then gently pat dry, before application. Apply a small, thin amount of the ointment or cream to the affected area one to three times daily, or as directed by a healthcare professional. The treated area may be covered with a sterile bandage if desired, particularly to protect the wound from further contamination. It is crucial not to apply this product to large areas of the body, to deep or puncture wounds, to animal bites, or to serious burns without prior consultation and explicit instruction from a physician. The duration of treatment should generally not exceed 7 days; if the condition persists, worsens, or if signs of infection (e.g., fever, spreading redness, pus) develop, discontinue use and seek immediate medical attention. Wash hands thoroughly before and after each application. This product is not intended for ophthalmic or otic use unless specifically formulated and indicated for such purposes, and contact with eyes, ears, or mucous membranes should be avoided. |
Safety & Warnings
Common Side Effects
- While generally well-tolerated when used as directed, topical application of this combination medication may lead to various side effects, primarily localized to the site of application.
- Common local reactions include mild irritation, redness (erythema), itching (pruritus), rash, swelling, and a transient stinging or burning sensation.
- Hypersensitivity reactions are a significant concern, particularly allergic contact dermatitis, which is most frequently attributable to neomycin.
- Symptoms of contact dermatitis may manifest as a delayed reaction, presenting as worsening redness, intense itching, blistering, or oozing at the application site.
- Although rare with proper topical use on intact skin, prolonged use or application to large areas of compromised skin, such as extensive burns or open wounds, can significantly increase systemic absorption of the active ingredients.
- This elevated absorption carries a theoretical risk of systemic adverse effects, including ototoxicity (hearing loss, vestibular dysfunction) and nephrotoxicity (kidney damage) primarily due to neomycin and polymyxin B, or central nervous system effects (e.
- g.
- , dizziness, drowsiness, confusion, tremors, seizures) and cardiovascular effects (e.
- g.
- , bradycardia, hypotension, cardiac arrest) due to lignocaine.
- Furthermore, prolonged or inappropriate use of topical antibiotics can alter the natural microbial flora, potentially leading to superinfection with non-susceptible organisms, including fungi, which may require additional treatment.
Serious Warnings
- Black Box Warning: This topical combination medication, Neomycin + Polymyxin B + Bacitracin + Lignocaine, *does not carry an FDA-mandated Black Box Warning*. Black Box Warnings, also known as boxed warnings, are the strongest warnings the FDA requires for prescription drug products when there is reasonable evidence of an association of a serious hazard with the drug. However, despite the absence of a formal boxed warning, healthcare providers and patients must be aware of several serious potential risks associated with the use of this product, particularly with inappropriate application, which are detailed below: **Serious Warnings:** 1. **Risk of Allergic Contact Dermatitis:** Neomycin is a well-known contact sensitizer. Prolonged or repeated topical application, especially to compromised or damaged skin, can induce or exacerbate allergic contact dermatitis. This reaction may manifest as an intensification of initial symptoms such as redness, itching, and swelling, or as new symptoms including blistering, oozing, and severe irritation at the application site. Patients who develop such signs of hypersensitivity should immediately discontinue use and consult a healthcare professional for evaluation and alternative treatment options. 2. **Potential for Systemic Absorption and Toxicity:** While systemic absorption is generally low when the product is applied correctly to intact skin, the risk significantly increases if the medication is applied to large surface areas, to broken, denuded, or extensively damaged skin (e.g., large burns, open wounds), or if used for prolonged periods. Elevated systemic absorption can lead to severe adverse effects: * **Ototoxicity and Nephrotoxicity:** Neomycin and Polymyxin B, when absorbed systemically, are known to cause irreversible ototoxicity (damage to the auditory and vestibular systems, potentially resulting in permanent hearing loss and balance impairment) and nephrotoxicity (kidney damage). This risk is particularly elevated in patients with pre-existing renal impairment, in neonates, or when used concomitantly with other known nephrotoxic or ototoxic medications. * **Lignocaine Systemic Toxicity:** Excessive systemic absorption of lignocaine can lead to central nervous system (CNS) effects, including lightheadedness, dizziness, drowsiness, confusion, blurred vision, tremors, muscle twitching, seizures, and unconsciousness. It can also cause significant cardiovascular effects such as bradycardia, hypotension, myocardial depression, and potentially cardiac arrest. Children, elderly patients, and individuals with cardiac or hepatic impairment are particularly vulnerable to lignocaine systemic toxicity. 3. **Risk of Superinfection:** Prolonged or indiscriminate use of topical antibiotic preparations can lead to an alteration in the normal microbial flora of the skin, potentially resulting in the overgrowth of non-susceptible bacteria or fungi. If new infections or a worsening of the original symptoms occur, or if there is no improvement within 7 days, the use of this product should be discontinued, and the patient's condition should be re-evaluated by a healthcare professional. 4. **Avoid Ocular and Aural Use:** This product is not formulated for ophthalmic use. When applied into the ear canal, especially in the presence of a perforated tympanic membrane, neomycin can directly access the middle and inner ear structures, leading to significant and potentially permanent ototoxicity and hearing loss. Therefore, strict adherence to the recommended dosage, duration of use, and specified application sites is paramount to minimize these potential serious risks. Any signs of systemic absorption or localized adverse reactions necessitate immediate medical consultation.
- This medication is strictly for external use on the skin only and should not be ingested.
- Avoid direct contact with eyes, inner ear, and mucous membranes (e.
- g.
- , mouth, nose, genitals).
- Discontinue use and consult a healthcare professional immediately if irritation, sensitization, or an allergic reaction (e.
- g.
- , worsening redness, itching, swelling, blistering) develops or intensifies.
- Neomycin, in particular, is a known sensitizer and can cause allergic contact dermatitis.
- Do not use this product on deep or puncture wounds, animal bites, serious burns, or large areas of the body without prior medical consultation, as significant systemic absorption of the active ingredients (neomycin, polymyxin B, lignocaine) can occur.
- Such absorption may lead to serious adverse effects, including ototoxicity and nephrotoxicity from the antibiotics, or central nervous system and cardiovascular toxicity from lignocaine.
- Patients with known hypersensitivity or allergic reactions to any of the components (neomycin, polymyxin B, bacitracin, lignocaine, or excipients) should avoid this product entirely.
- Prolonged use of topical antibiotics may lead to the overgrowth of non-susceptible organisms, including fungi, necessitating re-evaluation of the diagnosis and treatment regimen.
- Use with extreme caution in patients with impaired renal function if applying to large or broken skin areas, due to the increased risk of systemic toxicity.
- Pregnant or breastfeeding individuals should consult a healthcare provider before use.
How it Works (Mechanism of Action)
This medicinal product leverages the distinct and complementary mechanisms of its four active components to provide comprehensive management of minor skin infections and associated discomfort. **Neomycin**, an aminoglycoside antibiotic, exerts its potent bactericidal effect by irreversibly binding to the 30S ribosomal subunit of susceptible bacteria. This binding disrupts bacterial protein synthesis, leading to the production of non-functional proteins and ultimately bacterial cell death. It is particularly effective against many Gram-negative bacteria (e.g., Escherichia coli, Klebsiella, Proteus) and some Gram-positive bacteria (e.g., Staphylococcus aureus). **Polymyxin B**, a polypeptide antibiotic, acts as a cationic detergent. It disrupts the structural integrity of the outer and inner bacterial cell membranes, particularly in Gram-negative bacteria like Pseudomonas aeruginosa, by interacting with phospholipid components. This disruption leads to increased membrane permeability, leakage of intracellular contents, and subsequent cell death. **Bacitracin**, another polypeptide antibiotic, interferes with bacterial cell wall synthesis. It specifically inhibits the dephosphorylation of undecaprenyl pyrophosphate, a crucial lipid carrier involved in transporting peptidoglycan precursors across the bacterial membrane. This mechanism primarily targets Gram-positive bacteria, including Staphylococci and Streptococci. **Lignocaine (Lidocaine)**, a local anesthetic of the amide type, functions by reversibly stabilizing the neuronal membrane. It achieves this by inhibiting the ionic fluxes, specifically the rapid influx of sodium ions, which are essential for the initiation and conduction of nerve impulses. By blocking these sodium channels, lignocaine prevents the generation and propagation of pain signals from the peripheral nerves to the central nervous system, thereby producing localized anesthesia and effective relief from pain and itching.
Commercial Brands (Alternatives)
No other brands found for this formula.